恩利是全球第一个被批准用于中重度类风湿关节炎(RA) 治疗的TNF抑制剂,
也是全球第一个被批准用于强直性脊 柱炎(AS)治疗的TNF抑制剂。
是全球第一个具有十年上 市应用经验的TNF抑制剂。

>>走进恩利(视频)

注:如不能播放,请拖一下播放器滑块即可

>>恩利诞生全球纪事

二十世纪八十年代后期,Immunex的一个科学家团队发现了恩利分子。 1998年,恩利通过FDA认证用于治疗中重度RA(单用或与MTX联用)。 1999年,恩利通过FDA认证用于治疗中重度活动性青少年

>>恩利与欧洲类风湿关节炎患者的故事(一)

When Anne was first told she had rheumatoid arthritis (RA), her initial reaction wasn't shock or panic, but rather relief. She finally had a name, a diagnosis for what she was suffering from, and could begin to take action to manage it. Wit

>>恩利与欧洲类风湿关节炎患者的故事(二)

Ana was diagnosed with rheumatoid arthritis (RA) and systemic lupus erythematous. She hopes that by sharing her story with others who might identify with her experiences, she will motivate them and pass on her zest for life. The first sympt

页面